Amneal Pharmaceuticals announced the launch of its generic bimatoprost ophthalmic solution 0.01% on April 09 2026, becoming the first company to offer a generic version of LUMIGAN® for the treatment of elevated intraocular pressure in open‑angle glaucoma and ocular hypertension patients.
The new product is available in 2.5 mL, 5 mL and 7.5 mL bottles, expanding Amneal’s Affordable Medicines portfolio into the ophthalmology market—a high‑demand segment with limited generic competition.
The launch follows FDA approval of the abbreviated new drug application on September 23 2025 and builds on Amneal’s recent success in launching complex ophthalmic generics such as fluorometholone and prednisolone acetate.
Amneal’s Q4 2025 results—revenue of $814 million and adjusted EPS of $0.21—demonstrated strong performance, and the company now projects 2026 revenue of $3.05‑$3.15 billion, positioning the new product to contribute to continued growth.
The U.S. market for bimatoprost ophthalmic solution 0.01% was $719 million in the 12 months ending February 2026, underscoring the sizable opportunity for a lower‑cost generic.
Dr. Srinivas Kone, Senior Vice President and Chief Scientific Officer of Affordable Medicines, said, "We are pleased to bring another key ophthalmic therapy to our Affordable Medicines portfolio. As glaucoma prevalence continues to rise, particularly among the aging population, expanding access to effective treatments like bimatoprost is critical. This launch builds on our strong cadence of complex product introductions and represents an important growth driver for our Affordable Medicines segment."
By entering the ophthalmology market, Amneal aims to capture market share in a niche with limited competition, leveraging its expertise in complex generics to offer a cost‑effective alternative that could drive volume growth and margin expansion in the Affordable Medicines segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.